Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KOD |
---|---|---|
09:32 ET | 5678 | 2.71 |
09:41 ET | 808 | 2.715 |
09:43 ET | 202 | 2.74 |
09:50 ET | 2800 | 2.735 |
09:52 ET | 350 | 2.75 |
09:54 ET | 100 | 2.75 |
09:57 ET | 2763 | 2.75 |
10:01 ET | 100 | 2.735 |
10:06 ET | 400 | 2.7251 |
10:08 ET | 100 | 2.73 |
10:10 ET | 100 | 2.735 |
10:12 ET | 100 | 2.73 |
10:14 ET | 100 | 2.72 |
10:15 ET | 100 | 2.75 |
10:21 ET | 100 | 2.75 |
10:26 ET | 1600 | 2.75 |
10:28 ET | 100 | 2.75 |
10:32 ET | 1031 | 2.76 |
10:33 ET | 580 | 2.7507 |
10:37 ET | 601 | 2.77 |
10:39 ET | 360 | 2.765 |
10:42 ET | 1107 | 2.75 |
10:46 ET | 100 | 2.75 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kodiak Sciences Inc | 142.6M | -0.7x | --- |
Acumen Pharmaceuticals Inc | 146.0M | -2.3x | --- |
Context Therapeutics Inc | 138.7M | -1.7x | --- |
Inovio Pharmaceuticals Inc | 143.1M | -1.2x | --- |
Immunic Inc | 135.1M | -1.0x | --- |
Outlook Therapeutics Inc | 134.4M | -0.7x | --- |
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $142.6M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.34 |
EPS | $-3.77 |
Book Value | $5.06 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.